Considering that p73 is rarely mutated in cancer, pharmacological activation of the tumor-suppressive activities of p73 represents an attractive alternative strategy to treat cancer cells, in particular those where p53 is lost or mutated. This evidence concerns the gene TP53 and neoplasm.